{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"10.1","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"For Part B only. OS was defined as the time from the date of signed informed consent to the date of death from any cause. For patients who were still alive as of the data cut-off date, OS time was censored on the date of the patient's last contact (last contact for patients in post-discontinuation was the last date of contact in long-term follow-up eCRF).","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.","id":"OG000","title":"300 mg DKN-01 Part B (Q2W)"}],"paramType":"MEDIAN","populationDescription":"For patients who are still alive as of the data cut-off date, OS time will be censored on the date of the patient's last contact (last contact for patients in post-discontinuation = last Date of Contact in Long Term Follow-up eCRF).","reportingStatus":"POSTED","timeFrame":"Time from the date of signed informed consent to the date of death from any cause","title":"Overall Survival (OS) in Patients With Relapsed or Refractory NSCLC","type":"SECONDARY","unitOfMeasure":"Months"}